Eicosapentaenoic Acid Supplementation Changes Fatty Acid Composition and Corrects Endothelial Dysfunction in Hyperlipidemic Patients

Table 2

General characteristics of studied patients.

	Normolipidemic (𝑛=18)	Hyperlipidemic (𝑛=16)
		0M	1M	3M
Body weight, kg	56.1 ± 11.1	61.7 ± 12.0	62.6 ± 12.9	61.0 ± 11.4
Body mass index, kg/m^2	23.0 ± 3.3	26.3 ± 3.4*	26.8 ± 3.2*	25.0 ± 2.5
Waist circumference, cm	83.7 ± 9.1	91.4 ± 6.0*	95.4 ± 5.4*	92.0 ± 4.6*
Hip circumference, cm	93.2 ± 4.2	93.3 ± 5.1	96.3 ± 5.7	91.6 ± 4.8
Waist/Hip	0.90 ± 0.08	0.98 ± 0.05*	0.98 ± 0.09*	1.01 ± 0.06*
Systolic blood pressure, mmHg	120 ± 13	135 ± 20*	132 ± 21	131 ± 12
Diastolic blood pressure, mmHg	69 ± 9	75 ± 11	77 ± 15	77 ± 9
Heart rate, beats/min	64 ± 12	69 ± 14	77 ± 22	59 ± 12

Mean ± SD, *𝑃<0.05 versus normolipidemic.
0M, 1M, and 3M: baseline and 1 and 3 months after EPA treatment.